FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2801578506> ?p ?o ?g. }

• W2801578506 endingPage "2451" @default.
• W2801578506 startingPage "2442" @default.
• W2801578506 abstract "Abstract Neoadjuvant endocrine therapy has been reported to decrease tumor size, which leads to increased breast conservation rates. To improve the clinical response, metronomic chemotherapy with endocrine therapy is a promising strategy. A multicenter phase II single‐arm neoadjuvant trial with letrozole and cyclophosphamide was conducted. Eligibility criteria included postmenopausal status, T2–4 N0–1, and estrogen receptor‐positive breast carcinoma. Letrozole (2.5 mg) plus cyclophosphamide (50 mg) was given orally once a day for 24 weeks. The primary endpoint was the clinical response rate (CRR). To investigate anti‐angiogenic effects, circulating endothelial cells (CECs) were quantified using the CellSearch system. From October 2007 to March 2010, 41 patients were enrolled. The CRR was 67.5% (52.0–80.0%), which was above the prespecified threshold (65%). The conversion rate from total mastectomy to breast‐conserving surgery was 64% (18/28). Grade 3 or greater nonhematological toxicity was not reported. Clinical response was associated with improved disease‐free survival (DFS) ( P = 0.020). The increase in CEC counts at 8 weeks was observed in nonresponders ( P = 0.004) but not in responders. Patients with higher CEC counts at baseline or post‐treatment showed worse DFS than those with lower counts ( P < 0.001 at baseline and = 0.014 post‐treatment). Multivariate analysis showed that post‐treatment CEC counts but not pretreatment counts were independently correlated with DFS ( P = 0.046). In conclusion, neoadjuvant letrozole plus cyclophosphamide showed a good clinical response for postmenopausal patients with estrogen receptor‐positive breast cancer. CEC quantification is a promising tool for treatment monitoring and prognostic stratification for metronomic therapy following validation of our results in larger studies. Clinical trial registration number: UMIN000001331 Phase II study of neoadjuvant letrozole combined with low‐dose metronomic cyclophosphamide for postmenopausal women with endocrine‐responsive breast cancer (JBCRG‐07)" @default.
• W2801578506 created "2018-05-17" @default.
• W2801578506 creator A5003489811 @default.
• W2801578506 creator A5028012899 @default.
• W2801578506 creator A5037991551 @default.
• W2801578506 creator A5055151557 @default.
• W2801578506 creator A5057801765 @default.
• W2801578506 creator A5058163170 @default.
• W2801578506 creator A5061220478 @default.
• W2801578506 creator A5063851467 @default.
• W2801578506 creator A5067189124 @default.
• W2801578506 creator A5071117344 @default.
• W2801578506 creator A5091245889 @default.
• W2801578506 date "2018-05-07" @default.
• W2801578506 modified "2023-09-27" @default.
• W2801578506 title "A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells" @default.
• W2801578506 cites W1819686384 @default.
• W2801578506 cites W1972146805 @default.
• W2801578506 cites W1995692008 @default.
• W2801578506 cites W2009337734 @default.
• W2801578506 cites W2019607817 @default.
• W2801578506 cites W2024982960 @default.
• W2801578506 cites W2026423975 @default.
• W2801578506 cites W2029883816 @default.
• W2801578506 cites W2031871398 @default.
• W2801578506 cites W2032207130 @default.
• W2801578506 cites W2043457250 @default.
• W2801578506 cites W2048829586 @default.
• W2801578506 cites W2053543045 @default.
• W2801578506 cites W2060233529 @default.
• W2801578506 cites W2062071674 @default.
• W2801578506 cites W2084654918 @default.
• W2801578506 cites W2086960991 @default.
• W2801578506 cites W2090365682 @default.
• W2801578506 cites W2097698108 @default.
• W2801578506 cites W2098282622 @default.
• W2801578506 cites W2100256308 @default.
• W2801578506 cites W2113435829 @default.
• W2801578506 cites W2125589899 @default.
• W2801578506 cites W2130900820 @default.
• W2801578506 cites W2134444110 @default.
• W2801578506 cites W2137853125 @default.
• W2801578506 cites W2142334766 @default.
• W2801578506 cites W2162875441 @default.
• W2801578506 cites W2163940216 @default.
• W2801578506 cites W2165037690 @default.
• W2801578506 doi "https://doi.org/10.1002/cam4.1516" @default.
• W2801578506 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6010720" @default.
• W2801578506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29733541" @default.
• W2801578506 hasPublicationYear "2018" @default.
• W2801578506 type Work @default.
• W2801578506 sameAs 2801578506 @default.
• W2801578506 citedByCount "9" @default.
• W2801578506 countsByYear W28015785062019 @default.
• W2801578506 countsByYear W28015785062020 @default.
• W2801578506 countsByYear W28015785062021 @default.
• W2801578506 countsByYear W28015785062022 @default.
• W2801578506 countsByYear W28015785062023 @default.
• W2801578506 crossrefType "journal-article" @default.
• W2801578506 hasAuthorship W2801578506A5003489811 @default.
• W2801578506 hasAuthorship W2801578506A5028012899 @default.
• W2801578506 hasAuthorship W2801578506A5037991551 @default.
• W2801578506 hasAuthorship W2801578506A5055151557 @default.
• W2801578506 hasAuthorship W2801578506A5057801765 @default.
• W2801578506 hasAuthorship W2801578506A5058163170 @default.
• W2801578506 hasAuthorship W2801578506A5061220478 @default.
• W2801578506 hasAuthorship W2801578506A5063851467 @default.
• W2801578506 hasAuthorship W2801578506A5067189124 @default.
• W2801578506 hasAuthorship W2801578506A5071117344 @default.
• W2801578506 hasAuthorship W2801578506A5091245889 @default.
• W2801578506 hasBestOaLocation W28015785061 @default.
• W2801578506 hasConcept C121608353 @default.
• W2801578506 hasConcept C126322002 @default.
• W2801578506 hasConcept C126894567 @default.
• W2801578506 hasConcept C143998085 @default.
• W2801578506 hasConcept C203092338 @default.
• W2801578506 hasConcept C2776694085 @default.
• W2801578506 hasConcept C2776755627 @default.
• W2801578506 hasConcept C2777176818 @default.
• W2801578506 hasConcept C2777757722 @default.
• W2801578506 hasConcept C2778292576 @default.
• W2801578506 hasConcept C2778311097 @default.
• W2801578506 hasConcept C2778812593 @default.
• W2801578506 hasConcept C31760486 @default.
• W2801578506 hasConcept C530470458 @default.
• W2801578506 hasConcept C535046627 @default.
• W2801578506 hasConcept C71924100 @default.
• W2801578506 hasConcept C84606932 @default.
• W2801578506 hasConceptScore W2801578506C121608353 @default.
• W2801578506 hasConceptScore W2801578506C126322002 @default.
• W2801578506 hasConceptScore W2801578506C126894567 @default.
• W2801578506 hasConceptScore W2801578506C143998085 @default.
• W2801578506 hasConceptScore W2801578506C203092338 @default.
• W2801578506 hasConceptScore W2801578506C2776694085 @default.
• W2801578506 hasConceptScore W2801578506C2776755627 @default.
• W2801578506 hasConceptScore W2801578506C2777176818 @default.
• W2801578506 hasConceptScore W2801578506C2777757722 @default.
• W2801578506 hasConceptScore W2801578506C2778292576 @default.

• next